MEI Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MEI Pharma, Inc. - overview
Established
2000
Location
San Diego, CA, US
Primary Industry
Pharmaceuticals
About
MEI Pharma, Inc. focuses on developing innovative cancer therapies aimed at overcoming treatment resistance, with a commitment to improving patient outcomes through advanced therapeutic solutions. Founded in 2000 and headquartered in San Diego, US, MEI Pharma specializes in oncology. The company has received a total of USD 75.
00 mn through 7 deals, with the latest funding round being a PIPE led by CAM Capital and Vivo Capital. The CEO team includes Dan Gold, David Urso, and Matheno Bey. MEI Pharma specializes in innovative cancer therapies targeting drug resistance mechanisms found in conventional treatments. Their product pipeline focuses on hematologic malignancies and solid tumors, with Voruciclib as a flagship product currently in clinical trials, aimed at serving oncologists and healthcare institutions in North America and Europe.
For the year 2024, MEI Pharma reported revenue of USD 65. 30 mn and an EBITDA of USD 14. 93 mn, primarily generated through collaborations with research institutions and pharmaceutical companies. MEI Pharma plans to leverage recent funding from the PIPE round to advance their clinical pipeline.
The company is focused on launching new products and expanding into European markets by late 2025. Recent financial activities include the exit of Vivo Capital, Boxer Capital, CAM Capital, and Perceptive Advisors from their stake in MEI Pharma, although financial terms were not disclosed.
Current Investors
Vivo Capital, New Leaf Venture Partners, New Enterprise Associates
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Bioinformatics, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.meipharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
MEI Pharma, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | MEI Pharma, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | MEI Pharma, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | MEI Pharma, Inc. | - | ||||||||
| Private Placement/Follow on | Completed | MEI Pharma, Inc. | - | ||||||||
| PIPE | Completed | MEI Pharma, Inc. | - |
Displaying 1 - 5 of 6
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.